JP2017519502A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519502A5
JP2017519502A5 JP2016573854A JP2016573854A JP2017519502A5 JP 2017519502 A5 JP2017519502 A5 JP 2017519502A5 JP 2016573854 A JP2016573854 A JP 2016573854A JP 2016573854 A JP2016573854 A JP 2016573854A JP 2017519502 A5 JP2017519502 A5 JP 2017519502A5
Authority
JP
Japan
Prior art keywords
chain
antigen receptor
chimeric antigen
specific multi
fcεri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016573854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/063656 external-priority patent/WO2015193406A1/en
Publication of JP2017519502A publication Critical patent/JP2017519502A/ja
Publication of JP2017519502A5 publication Critical patent/JP2017519502A5/ja
Pending legal-status Critical Current

Links

JP2016573854A 2014-06-17 2015-06-17 Cd123特異的多重鎖キメラ抗原受容体 Pending JP2017519502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470361 2014-06-17
DKPA201470361 2014-06-17
PCT/EP2015/063656 WO2015193406A1 (en) 2014-06-17 2015-06-17 Cd123 specific multi-chain chimeric antigen receptor

Publications (2)

Publication Number Publication Date
JP2017519502A JP2017519502A (ja) 2017-07-20
JP2017519502A5 true JP2017519502A5 (enExample) 2018-07-12

Family

ID=51062604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573854A Pending JP2017519502A (ja) 2014-06-17 2015-06-17 Cd123特異的多重鎖キメラ抗原受容体

Country Status (6)

Country Link
US (1) US20180134795A1 (enExample)
EP (1) EP3158064A1 (enExample)
JP (1) JP2017519502A (enExample)
AU (1) AU2015276131A1 (enExample)
CA (1) CA2949325A1 (enExample)
WO (1) WO2015193406A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201910814T4 (tr) 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
CN107708710A (zh) 2015-03-17 2018-02-16 嵌合体生物工程公司 Smart CAR装置,DE CAR多肽,Side CAR及其使用
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
US10222369B2 (en) 2016-05-17 2019-03-05 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
MA45498A (fr) * 2016-06-16 2019-04-24 Memorial Sloan Kettering Cancer Center Cellules treg génétiquement modifiées
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
CN110121352B (zh) 2016-09-01 2020-12-11 嵌合体生物工程公司 Gold优化的car t-细胞
DK3757120T3 (da) * 2016-10-04 2022-07-25 Prec Biosciences Inc Co-stimulerende domæner til anvendelse i genetisk modificerede celler
TW201934575A (zh) 2018-02-11 2019-09-01 大陸商江蘇恆瑞醫藥股份有限公司 一種分離的嵌合抗原受體以及包含其的修飾t細胞及用途
EP3806870A4 (en) 2018-02-13 2021-12-22 Chimera Bioengineering, Inc. COORDINATION OF GENE EXPRESSION USING RNA DESSTABILIZATION ELEMENTS
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
US20210046117A1 (en) 2019-08-18 2021-02-18 Chimera Bioengineering, Inc. Combination Therapy with Gold Controlled Transgenes
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021260696A1 (en) * 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
WO2023000036A1 (en) * 2021-07-22 2023-01-26 The Westmead Institute for Medical Research Chimeric antigen receptor useful in treating cancer
EP4408894A4 (en) 2021-09-29 2025-08-20 Chimera Bioengineering Inc Compositions and methods for anti-tnmuc1 gold car t-cells
US20250195658A1 (en) * 2022-01-12 2025-06-19 St. Jude Children's Research Hospital, Inc. Bispecific chimeric antigen receptors targeting grp78 and cd123 or grp78 and b7h3
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024094004A1 (zh) * 2022-11-03 2024-05-10 重庆精准生物技术有限公司 靶向cd123的全人源抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
ES2550639T3 (es) * 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2850106B1 (en) * 2012-05-18 2022-03-23 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
AU2013312838B2 (en) * 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof

Similar Documents

Publication Publication Date Title
JP2017518071A5 (enExample)
FI4324851T3 (fi) BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä
JP2017522893A5 (enExample)
Sasidharan Nair et al. Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
JP2020511136A5 (enExample)
JP2021087455A5 (enExample)
JP2017513478A5 (enExample)
JP2020517295A5 (enExample)
JP2019527557A5 (enExample)
JP2017524367A5 (enExample)
JP2021094037A5 (enExample)
JP2018525006A5 (enExample)
JP2018504094A5 (enExample)
HRP20211978T1 (hr) Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe
JP2021531004A5 (enExample)
JP2020114264A5 (enExample)
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
JP2021500881A5 (enExample)
JP2022501043A5 (enExample)
FI3710067T3 (fi) Polypeptidejä sisältävä d-domeeni ja niiden käyttötarkoitukset
JP2018518939A5 (enExample)
JP2020513754A5 (enExample)
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe
JP2016520074A5 (enExample)
IL275391B1 (en) CTLA-4-binding antibodies and their uses